Philips IntelliSpace Precision Medicine Oncology Pathways powered by Dana-Farber is now live
Estimated reading time: 4-6 minutes
With oncology treatments evolving faster than clinical teams can adapt, identifying relevant information to help inform the decision-making process is quite complex. Clinicians continue to struggle to leverage the right information at the right time to develop and implement precision medicine programs for personalized cancer care. Multiple data sources are emerging each day, providing input ranging from new drug options, to active clinical trials, to genomics, making treating cancer increasingly difficult. By 2020, it is expected that medical data will double every 73 days, and the average person will generate more than 1 million gigabytes of health-related data in their lifetime .
Henk van Houten, Chief Technology Officer at Philips, pointed out in a recent article, the concept of personalized care is the cornerstone of oncology research and cancer treatment. Yet, for all the progress that has been made over the past few decades, challenges still remain. “Even cancers with the same site of origin, like lung cancer, can vary from one person to the other – and respond differently to the same treatment,” Henk stated.
Access to the expertise of more than 300 Dana Farber experts
In 2018, Philips announced a partnership with the Dana-Farber Cancer Institute, a leading center of cancer research and treatment, to incorporate the institute’s Clinical Pathways in the Philips IntelliSpace Oncology platform. Since August 2019, just a little over a year from announcing the collaboration, the Oncology Pathways platform is now live. Philips IntelliSpace Precision Medicine Oncology Pathways powered by Dana-Farber provides access to the expertise of more than 300 oncologists, scientists, pharmacists and a team of data scientists and informatics experts at Dana-Farber Cancer Institute (DFCI). The solution will help oncologists efficiently reach the most appropriate cancer treatments for patients, based on a unified view of the patient across diagnostic modalities.
With Dana-Farber’s Clinical Pathways, oncologists get recommendations for specific therapies – and clinical trials – matched to patient characteristics, such as specific gene mutations. Recommendations are based on the latest scientific insights and are continuously updated, enabling treatment selection that is more personalized and standardized at the same time. The solution delivers data-driven guidance to help the broader cancer care team more easily navigate the increasing complexities of cancer care diagnostics and treatment options, and personalize each patient’s treatment based on their biological characteristics. The strength of Philips’ technical ingenuity and DFCI’s clinical expertise is extending best practices of a renowned cancer institute to the global oncology community.
The Dana-Farber Pathways platform enables busy oncologists to function as efficiently as possible by providing them at-their-fingertips access to predetermined treatment recommendations based on review of the most recent data by their peers
Joseph O. Jacobson
MD, MSc, Chief Quality Officer at the Dana-Farber Cancer Institute
“The Dana-Farber Pathways platform enables busy oncologists to function as efficiently as possible by providing them at-their-fingertips access to predetermined treatment recommendations based on review of the most recent data by their peers,” said Joseph O. Jacobson, MD, MSc, Chief Quality Officer at the Dana-Farber Cancer Institute. “The pathways platform is easily accessible in the midst of a busy clinical practice, guides physicians to the recommended treatment in a visually intuitive way, provides one-click access to supporting literature and creates a regimen-specific consent form. Of equal importance, the platform facilitates the selection of off-pathway choices when the on-pathway recommendation is not the best option for the patient.”
During the recent American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Philips showcased its capabilities to provide access to top-tier expert content for oncology decision making from Dana-Farber Pathways, including optional personalized therapies listing and recommended clinical trials matching to deliver guidance and trust from Dana-Farber to other locations and institutions around the country and around the world where patients receive care. Hear more from Dana-Farber’s Dr. David Jackman and Carole Tremonti on why one of the leading cancer institutes in the world chose Philips to power its Oncology Pathways to help improve cancer care.
More information on how Philips and Dana-Farber integrate data into informed treatment options is available here.
Philips IntelliSpace Precision Medicine Oncology Pathways powered by Dana-Farber is currently available in the U.S. and selected international markets.
By clicking on the link, you will be leaving the official Royal Philips Healthcare ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.